Gilvetmab

Product Grant Program Award Recipient

Cycle 2 Award Recipients

Timothy M. Fan, DVM, PhD, DACVIM (Oncology) – University of Illinois

Daiki Kato, DVM, PhD – The University of Tokyo

Takayuki Nakagawa, DVM, PhD – The University of Tokyo

Investigating the immune and cytoreductive activities of gilvetmab alone and in combination with indoleamine 2,3-dioxygenase inhibition in canine urothelial carcinoma of the bladder.

Yoshimi Iwaki, DVM, MS, DACVIM & DAiCVIM (Oncology) – University of Missouri

Jeffrey N. Bryan, DVM, MS, PhD, DACVIM (Oncology) – University of Missouri

Adjuvant gilvetmab treatment for completely resected stage III canine pulmonary carcinomas.

Tiffany Martin, D.V.M., M.S., Diplomate ACVR (Radiation Oncology) – Colorado State University

Kristen Weishaar, D.V.M., M.S., Diplomate ACVIM (Oncology) – Colorado State University

Doug Thamm, V.M.D., Diplomate ACVIM (Oncology) – Colorado State University

Combination of hypofractionated radiation therapy and gilvetmab for the treatment of regionally extensive cutaneous or subcutaneous mast cell tumors in dogs.

Kristen Weishaar, D.V.M., M.S., Diplomate ACVIM (Oncology) – Colorado State University

Doug Thamm, V.M.D., Diplomate ACVIM (Oncology) – Colorado State University

Combination therapy with gilvetmab and toceranib in dogs with measurable mast cell disease.

Chelsea Tripp, DVM, MS, DACVIM (Oncology) – Owner, Bridge Animal Referral Center, Edmonds, WA

Mark J. Mamula, PhD., Professor of Medicine – Yale Cancer Center

Hester A. Doyle, PhD., Research Scientist – Yale University School of Medicine

Natalia Shulzhenko, M.D., PhD., Associate Professor – Oregon State University, Carlson College of Veterinary Medicine

Immunotherapy in the Treatment of Canine Hemangiosarcoma.